Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy
Patil PA, Zhang X. Pathologic Manifestations of Gastrointestinal and Hepatobiliary Injury in Immune Checkpoint Inhibitor Therapy. Archives Of Pathology & Laboratory Medicine 2020, 145: 571-582. PMID: 32338534, DOI: 10.5858/arpa.2020-0070-ra.Peer-Reviewed Original ResearchConceptsHepatobiliary injuryCheckpoint inhibitorsCPI therapyActive colitisPathologic manifestationsCytotoxic T-lymphocyte-associated protein 4 inhibitorsT-lymphocyte-associated protein 4 inhibitorsImmune checkpoint inhibitor therapyDeath ligand 1 (PD-L1) inhibitorsAdverse effectsChronic active colitisAdministration of steroidsCheckpoint inhibitor therapyDeath receptor-1Immune checkpoint inhibitorsBile duct injuryChronic active gastritisLigand 1 inhibitorsNodular regenerative hyperplasiaSecondary sclerosing cholangitisDifferential diagnostic considerationsProtein 4 inhibitorsSeverity of injuryIschemic colitisPanlobular hepatitisMorphological spectrum of immune check‐point inhibitor therapy‐associated gastritis
Johncilla M, Grover S, Zhang X, Jain D, Srivastava A. Morphological spectrum of immune check‐point inhibitor therapy‐associated gastritis. Histopathology 2020, 76: 531-539. PMID: 31692018, DOI: 10.1111/his.14029.Peer-Reviewed Original ResearchConceptsImmune check-point inhibitor therapyCheck-point inhibitor therapyImmune-related adverse eventsImmune check point inhibitorsMorphological spectrumIntra-epithelial lymphocytosisCheck point inhibitorsChronic active gastritisInflammatory bowel diseaseMedical chart reviewCytotoxic T cellsDrug-induced gastritisPredominant histological patternDistribution of injuriesVariety of tumorsMechanism of actionSteroid therapyGastrointestinal injuryActive gastritisAdverse eventsChart reviewClinical suspicionMedication withdrawalBowel diseaseInhibitor therapy